| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
The molecular target of Cannabigerol monomethyl ether is not well-defined, but it is presumed to interact with the same receptors as other phytocannabinoids, namely the cannabinoid receptor type 1 (CB1) and type 2 (CB2), albeit with different affinities due to the methylation of the phenolic hydroxyl group. The 6'-methoxy modification likely reduces its affinity for CB1 and CB2 compared to cannabigerol (CBG), making it a potential neutral antagonist or lower-affinity agonist. It may also interact with non-cannabinoid targets such as transient receptor potential (TRP) channels (e.g., TRPA1, TRPV1, TRPM8) and the serotonin 5-HT1A receptor, similar to other cannabinoids. As a methylated derivative, it is more lipophilic and may have altered pharmacokinetic properties.
|
|---|---|
| ln Vitro |
Cannabigerol monomethyl ether is primarily used as an analytical standard, and its in vitro biological activity is not extensively characterized. However, based on studies of related cannabinoids, it may exhibit anti-inflammatory, analgesic, or anti-anxiety effects, but with reduced potency compared to cannabigerol (CBG). The methylation of the C-6' hydroxyl group is expected to significantly alter its binding to CB1 and CB2 receptors, as the phenolic OH is critical for hydrogen bonding interactions with these receptors. In vitro activity data (e.g., binding affinity EC50/IC50, functional activity) for CBGM is not publicly available. It is likely less active at CB1 and CB2 than CBG, which has a Ki of approximately 200-400 nM at CB1 and 100-300 nM at CB2. CBGM may retain activity at other targets, such as the transient receptor potential channels (TRPs) or the GPR55 receptor. Further studies are required to define its pharmacological profile.
|
| ln Vivo |
In vivo studies for Cannabigerol monomethyl ether have not been reported in the public literature. As a minor cannabinoid and research standard, it has not been systematically evaluated in animal models for pharmacological activity. It is not a drug candidate and is used as a reference compound for analytical chemistry and forensic toxicology. Any potential in vivo effects would be expected to be similar to those of cannabigerol (CBG), which has been shown to have anti-inflammatory, analgesic, and anti-convulsant effects in rodent models, but with potentially lower potency due to the methylation. No specific in vivo data is available for CBGM.
|
| Enzyme Assay |
Non-cell-based assays for Cannabigerol monomethyl ether are primarily analytical methods for its detection and quantification. A standard protocol involves high-performance liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). A C18 reverse-phase column (e.g., 150 × 4.6 mm, 5 um) is used at 40degC. The mobile phase consists of 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B). A gradient elution is performed: 0-5 min 40-60% B, 5-10 min 60-85% B, 10-12 min 85-95% B, hold at 95% B for 5 min, then re-equilibrate. The flow rate is 0.5 mL/min, and injection volume is 5-10 uL. Detection is performed using an electrospray ionization (ESI) source in positive ion mode, with multiple reaction monitoring (MRM) transitions: m/z 331.3 → 245.3 (for CBGM) and appropriate internal standard (e.g., CBGM-d3). Calibration curves are prepared by spiking known concentrations of the standard (0.5-500 ng/mL) into matrix (e.g., plasma, plant extract). For binding affinity studies, a radioligand binding assay using human CB1 or CB2 receptors expressed in HEK293 or CHO cell membranes can be used. Membranes (20-50 ug protein) are incubated with 3H-CP55,940 (1 nM) and varying concentrations of CBGM (0.1-10,000 nM) in binding buffer (50 mM Tris-HCl pH 7.4, 5 mM MgCl2, 1 mM EDTA, 0.1% BSA) for 90 minutes at 30degC. Non-specific binding is determined in the presence of 10 uM unlabeled CP55,940. Bound and free ligand are separated by filtration through GF/B filters, and radioactivity is counted. Ki values are calculated by competitive binding analysis. However, such data is not publicly available for CBGM.
|
| Cell Assay |
Cell-based assays for Cannabigerol monomethyl ether are not reported, as its primary use is as an analytical standard. For potential cell-based studies, standard cannabinoid activity assays could be adapted. For example, CB1 functional activity can be assessed using an assay for GTPgammaS binding or cAMP accumulation. For the GTPgammaS binding assay, CHO cells stably expressing human CB1 receptor are lysed and membranes are prepared. Membranes (20-30 ug) are incubated with 100 uM GDP, 0.1 nM 35S-GTPgammaS, and varying concentrations of CBGM (0.1-1000 nM) in assay buffer (20 mM HEPES pH 7.4, 100 mM NaCl, 5 mM MgCl2) for 60 minutes at 30degC. Bound radioactivity is separated by filtration and counted. For cAMP accumulation, HEK293-CB1 cells are seeded in 96-well plates and treated with forskolin (10 uM) to stimulate cAMP production, with or without CBGM. After 30 minutes, cAMP levels are measured using a competitive ELISA or HTRF kit. The EC50 for inhibition of cAMP (for agonists) is calculated. Similar assays can be performed for CB2. However, due to the methylation of the hydroxyl group, CBGM is expected to have low potency in these assays. Given its primary use as an analytical reference, cell-based activity data is not a priority for research use.
|
| Animal Protocol |
In vivo protocols are not applicable for Cannabigerol monomethyl ether as it is not an investigational drug. For researchers who wish to use it as an internal standard in pharmacokinetic studies, a typical protocol involves dosing animals (e.g., mice) with a parent compound (e.g., cannabigerol). Blood (e.g., 50 uL) is collected at various time points (0-24 h) and processed by protein precipitation with acetonitrile (containing CBGM as an internal standard at a fixed concentration, e.g., 10 ng/mL). After centrifugation, the supernatant is analyzed by LC-MS/MS as described above. The concentration of the parent compound is calculated by comparing the peak area ratio (parent/IS) to a calibration curve. CBGM itself would not be administered, nor would its own in vivo pharmacokinetics be studied.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Cannabigerol monomethyl ether is not available. As a chemical standard, it is not intended for in vivo administration. Physicochemical properties (MW 330.5, LogP ~6-7, high lipophilicity) suggest that if administered, it would be rapidly absorbed, extensively distributed to tissues (high Vd), metabolized by CYP450 enzymes (likely CYP2C9 and CYP3A4), and excreted primarily in feces. Its methyl ether group could be cleaved by CYP450 enzymes to yield cannabigerol, which would then be further metabolized. However, as a research standard, it is used only for analytical purposes and is not formulated for in vivo use. Stability: the compound should be stored as a solution (e.g., in acetonitrile or DMSO) at -20degC, protected from light, and is stable for at least 2 years.
|
| Toxicity/Toxicokinetics |
No toxicity data is available for Cannabigerol monomethyl ether, as it is not administered to animals or humans. Standard safety precautions for handling organic solvents and analytical standards apply, including using PPE (gloves, lab coat, goggles) and working in a fume hood when handling the powder or concentrated solutions. The compound is classified as an analytical reference standard and is not intended for human or veterinary use. It is not considered hazardous for routine laboratory handling if appropriate safety measures are taken. No genotoxicity, carcinogenicity, or reproductive toxicity studies have been conducted.
|
| References |
[1]. Linciano P, Citti C, Russo F, et al. Identification of a new cannabidiol n-hexyl homolog in a medicinal cannabis variety with an antinociceptive activity in mice: cannabidihexol. Sci Rep. 2020;10(1):22019. Published 2020 Dec 16.
|
| Additional Infomation |
CBGM (Item No. 9003893) is an analytical reference standard categorized as a phytocannabinoid. It is a synthetic compound and is not extracted from cannabis for routine research. It is supplied as a solution in acetonitrile (e.g., 10 mg/mL) or as a solid (if ordered from other suppliers). The product is intended for research and forensic applications, such as the quantification of cannabinoids in plant material, biological fluids, and edibles using LC-MS/MS or GC-MS. It is also useful for quality control in cannabis research and for studying the metabolism and pharmacology of methylated cannabinoids. CBGM is not a drug and is not approved by the FDA for any medical use. It is stored at -20degC in a sealed, light-resistant container. Purity is typically ≥98% by HPLC. It is a controlled substance in some jurisdictions due to its structural similarity to Schedule I cannabinoids, and researchers must comply with local regulations for handling and disposal of cannabis-related compounds.
|
| Molecular Formula |
C22H34O2
|
|---|---|
| Molecular Weight |
330.50
|
| Exact Mass |
330.256
|
| CAS # |
29106-17-0
|
| PubChem CID |
71446857
|
| Appearance |
Light yellow to yellow liquid
|
| LogP |
6.368
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
24
|
| Complexity |
393
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCC1=CC(O)=C(C/C=C(\CC/C=C(\C)/C)/C)C(OC)=C1
|
| InChi Key |
KASVLYINZPAMNS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H34O2/c1-6-7-8-12-19-15-21(23)20(22(16-19)24-5)14-13-18(4)11-9-10-17(2)3/h10,13,15-16,23H,6-9,11-12,14H2,1-5H3
|
| Chemical Name |
2-(3,7-dimethylocta-2,6-dienyl)-3-methoxy-5-pentylphenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (151.29 mM)
H2O: < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (7.56 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (7.56 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.56 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0257 mL | 15.1286 mL | 30.2572 mL | |
| 5 mM | 0.6051 mL | 3.0257 mL | 6.0514 mL | |
| 10 mM | 0.3026 mL | 1.5129 mL | 3.0257 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
